evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Trial design and protocol paper reporting no clinical outcome data
PubMed 39780249 · doi:10.1186/s13195-024-01666-7
What was done
This paper describes the design of evoke and evoke+, two randomized, double-blind, placebo-controlled phase 3 trials evaluating once-daily oral semaglutide versus placebo in early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid pathology. An anticipated 1,840 participants per trial (aged 55–85 years) were randomized 1:1 to oral semaglutide (dose-escalated across 8 weeks to 14 mg daily) or placebo for 156 weeks (104-week main phase plus a 52-week blinded extension). The primary outcome is change from baseline to week 104 on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) score, alongside plasma and cerebrospinal fluid biomarker sub-studies.
What was found
This publication reports trial design, eligibility criteria, and endpoints only; no clinical efficacy or safety outcome data are reported. Trial enrollment closed in September 2023, with main phase completion expected in September 2025 and extension completion in October 2026.
Why it matters
These are the first large-scale phase 3 trials testing whether a GLP-1 receptor agonist can act as a disease-modifying therapy in Alzheimer's disease via multimodal neuroprotective and anti-inflammatory mechanisms.
Limits
This report contains no clinical results. Final efficacy, cognitive outcomes, adverse effect rates, and biomarker responses cannot be determined until trial completion and unblinding.
Cited by
- supports GLP-1 receptor agonist medications are currently being evaluated in major Alzheimer's disease clinical trials in non-overweight and non-obese populations.